The FDA has approved Vykat XR (diazoxide choline) for the treatment of hyperphagia in adults and pediatric patients 4 years ...

The FDA’s approval of VYKAT XR for the treatment of hyperphagia in patients with PWS came with a clean label and reasonable monitoring requirements. This outcome represents a best-case scenario ...

The FDA’s approval of VYKAT XR for the treatment of hyperphagia in patients with PWS came with a clean label and reasonable monitoring requirements. This outcome represents a best-case scenario for ...

The United States Food and Drug Administration (US FDA) has approved VYKAT™ XR, a significant milestone as the first approved treatment for hyperphagia in Prader-Willi syndrome (PWS).

H.C. Wainwright raised the firm’s price target on Soleno Therapeutics (SLNO) to $100 from $70 and keeps a Buy rating on the shares after the ...

The United States Food and Drug Administration (US FDA) has approved VYKAT™ XR, a significant milestone as the first approved treatment for hyperphagia in Prader-Willi syndrome (PWS).

Over the last 7 days, the United States market has dropped 3.4%, yet it remains up by 6.1% over the past year, with earnings anticipated to grow by 14% annually in the coming years. In this context, ...

A new drug could change everything for children like seven-year-old daughter, Liliana, who has Prader-Willi syndrome, a rare ...